Omalizumab versus cyclosporin-a for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?

Kocatürk, EmekEngin, B.Özdemir, Mehmet AkifKüçük, Özlem SuCan, PelinÖrnek, SerdarHasal, EdaAtakan, Nilgün2024-11-262024-11-262019-08-010105-4538https://hdl.handle.net/11452/48479Bu çalışma, 01-05, Temmuz 2019 tarihleri arasında Lisbon[Portekiz]’da düzenlenen Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)’da bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessScience & technologyLife sciences & biomedicineImmunologyAllergyOmalizumab versus cyclosporin-a for the treatment of chronic spontaneous urticaria: Are there specific patient characteristics or biomarkers to indicate response to treatment?Meeting Abstract00048025400322448448574, Supplement 106, Special Issue SI